Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARQT shares.
View ARQT analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 12 month price objectives for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $8.00 to $50.00. On average, they anticipate the company's stock price to reach $26.56 in the next year. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts.

Arcutis Biotherapeutics' stock was trading at $3.23 at the start of the year. Since then, ARQT stock has increased by 212.4% and is now trading at $10.09.
View the best growth stocks for 2024 here.

Arcutis Biotherapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 19,260,000 shares, an increase of 28.5% from the March 15th total of 14,990,000 shares. Based on an average daily trading volume, of 4,760,000 shares, the short-interest ratio is presently 4.0 days.
View Arcutis Biotherapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ARQT earnings forecast.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.08. The company earned $13.53 million during the quarter, compared to analysts' expectations of $11.78 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 294.85% and a negative net margin of 439.79%. During the same period last year, the firm earned ($1.18) EPS.

ETFs with the largest weight of Arcutis Biotherapeutics (NASDAQ:ARQT) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV).

Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

Arcutis Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.15%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe.
View institutional ownership trends.

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.